Nöronal Seroid Lipofuksinozis ve Görüntüleme Bulguları

Williams RE, Mole SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology. 2012;79(2):183-191.

Simonati A, Williams RE. Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview. Frontiers in Neurology. 2022;13.

Haddad SE, Khoury M, Daoud M, Kantar R, Harati H, Mousallem T, et al. CLN5 and CLN8 protein association with ceramide synthase: Biochemical and proteomic approaches. Electrophoresis. 2012;33(24):3798-3809.

Schulz A, Mousallem T, Venkataramani M, Persaud-Sawin D-A, Zucker A, Luberto C, et al. The CLN9 Protein, a Regulator of Dihydroceramide Synthase. Journal of Biological Chemistry. 2006;281(5):2784-2794.

Mole SE, Anderson G, Band HA, Berkovic SF, Cooper JD, Kleine Holthaus SM, et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019;18(1):107-116.

Nosková L, Stránecký V, Hartmannová H, Přistoupilová A, Barešová V, Ivánek R, et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet. 2011;89(2):241-252.

Naseri N, Sharma M, Velinov M. Autosomal dominant neuronal ceroid lipofuscinosis: Clinical features and molecular basis. Clin Genet. 2021;99(1):111-118.

Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161-178.

Kohlschütter A, Schulz A, Bartsch U, Storch S. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses. CNS Drugs. 2019;33(4):315-325.

Kose M, Kose E, Ünalp A, Yılmaz Ü, Edizer S, Tekin HG, et al. Neuronal ceroid lipofuscinosis: genetic and phenotypic spectrum of 14 patients from Turkey. Neurological Sciences. 2021;42(3):1103-1111.

Panjeshahi S, Karimzadeh P, Movafagh A, Ahmadabadi F, Rahimian E, Alijanpour S, et al. Clinical and genetic characterization of neuronal ceroid lipofuscinoses (NCLs) in 29 Iranian patients: identification of 11 novel mutations. Human Genetics. 2023;142(8):1001-1016.

Ben Younes T, Kraoua I, Snanoudj S, Klaa H, Benrhouma H, Rouissi A, et al. Neuronal ceroïd-lipofuscinosis: Clinical, electroencephalographic, imaging, and genetic study of a maghrebian series. Clin Genet. 2022;102(2):157-160.

Guelbert G, Venier AC, Cismondi IA, Becerra A, Vazquez JC, Fernández EA, et al. Neuronal ceroid lipofuscinosis in the South American-Caribbean region: An epidemiological overview. Front Neurol. 2022;13:920421.

Gowda VK, Vegda H, Sugumar K, Narayanappa G, Srinivasan VM, Santhoshkumar R, et al. Neuronal Ceroid Lipofuscinosis: Clinical and Laboratory Profile in Children from Tertiary Care Centre in South India. J Pediatr Genet. 2021;10(4):266-273.

Ardicli D, Haliloglu G, Gocmen R, Gunbey C, Topcu M. Unraveling neuronal ceroid lipofuscinosis type 2 (CLN2) disease: A tertiary center experience for determinants of diagnostic delay. Eur J Paediatr Neurol. 2021;33:94-98.

Refeat MM, Naggar WE, Saied MME, Kilany A. Whole exome screening of neurodevelopmental regression disorders in a cohort of Egyptian patients. neurogenetics. 2023;24(1):17-28.

Ben Younes T, Kraoua I, Snanoudj S, Klaa H, Benrhouma H, Rouissi A, et al. Neuronal ceroïd-lipofuscinosis: Clinical, electroencephalographic, imaging, and genetic study of a maghrebian series. Clinical Genetics. 2022;102(2):157-160.

Lourenço CM, Pessoa A, Mendes CC, Rivera-Nieto C, Vergara D, Troncoso M, et al. Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world. J Paediatr Child Health. 2021;57(4):519-525.

Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K, Goebel HH, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112(4):347-354.

Worgall S, Kekatpure MV, Heier L, Ballon D, Dyke JP, Shungu D, et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology. 2007;69(6):521.

Orlin A, Sondhi D, Witmer MT, Wessel MM, Mezey JG, Kaminsky SM, et al. Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function. PLoS One. 2013;8(8):e73128.

Kovacs KD, Patel S, Orlin A, Kim K, Van Everen S, Conner T, et al. Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease. Ophthalmology Retina. 2020;4(7):728-736.

Purzycka-Olewiecka JK, Hetmańczyk-Sawicka K, Kmieć T, Szczęśniak D, Trubicka J, Krawczyński M, et al. Deterioration of visual quality and acuity as the first sign of ceroid lipofuscinosis type 3 (CLN3), a rare neurometabolic disease. Metabolic Brain Disease. 2023;38(2):709-715.

Abdennadher M, Inati S, Soldatos A, Norato G, Baker EH, Thurm A, et al. Seizure phenotype in CLN3 disease and its relation to other neurologic outcome measures. J Inherit Metab Dis. 2021;44(4):1013-1020.

Ostergaard JR. Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease). Frontiers in Psychiatry. 2023;14.

Nielsen AK, Drack AV, Ostergaard JR. Cataract and Glaucoma Development in Juvenile Neuronal Ceroid Lipofuscinosis (Batten Disease). Ophthalmic Genetics. 2015;36(1):39-42.

Marshall FJ, de Blieck EA, Mink JW, Dure L, Adams H, Messing S, et al. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology. 2005;65(2):275-279.

Wibbeler E, Nickel M, Schwering C, Schulz A, Mink JW. The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample. Eur J Paediatr Neurol. 2022;38:62-65.

Rietdorf K, Coode EE, Schulz A, Wibbeler E, Bootman MD, Ostergaard JR. Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidity. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2020;1866(9):165643.

Fukumura S, Saito Y, Saito T, Komaki H, Nakagawa E, Sugai K, et al. Progressive conduction defects and cardiac death in late infantile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2012;54(7):663-666.

Amytice M, Kenneth AM. Teaching NeuroImage: Low-Frequency Photoparoxysmal Response in a Patient With Neuronal Ceroid Lipofuscinosis Type 2. Neurology. 2023;101(4):e459.

Trivisano M, Ferretti A, Calabrese C, Pietrafusa N, Piscitello L, Carfi' Pavia G, et al. Neurophysiological Findings in Neuronal Ceroid Lipofuscinoses. Frontiers in Neurology. 2022;13.

Dulz S, Schwering C, Wildner J, Spartalis C, Schuettauf F, Bartsch U, et al. Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease). Br J Ophthalmol. 2023;107(10):1478-1483.

Ho M-L, Wirrell EC, Petropoulou K, Sakonju A, Chu D, Seratti G, et al. Role of Electroencephalogram (EEG) and Magnetic Resonance Imaging (MRI) Findings in Early Recognition and Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 Disease. Journal of Child Neurology. 2022;37(12-14):984-991.

Kuper WFE, Oostendorp M, van den Broek BTA, van Veghel K, Nonkes LJP, Nieuwenhuis EES, et al. Quantifying lymphocyte vacuolization serves as a measure of CLN3 disease severity. JIMD Rep. 2020;54(1):87-97.

Anderson G, Smith VV, Malone M, Sebire NJ. Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre. J Clin Pathol. 2005;58(12):1305-1310.

Nickel M, Gissen P, Greenaway R, Cappelletti S, Hamborg C, Ragni B, et al. Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis? Neuropediatrics. 2023.

Wibbeler E, Wang R, Reyes EL, Specchio N, Gissen P, Guelbert N, et al. Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series. J Child Neurol. 2021;36(6):468-474.

Crain AM, Kitchen DL, Godiyal N, Pfeifer CM. MRI findings in neuronal ceroid lipofuscinosis. Radiol Case Rep. 2020;15(11):2375-2377.

Markham A. Cerliponase Alfa: First Global Approval. Drugs. 2017;77(11):1247-1249.

de Los Reyes E, Lehwald L, Augustine EF, Berry-Kravis E, Butler K, Cormier N, et al. Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics. Pediatr Neurol. 2020;110:64-70.

Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, et al. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. New England Journal of Medicine. 2018;378(20):1898-1907.

Sondhi D, Kaminsky SM, Hackett NR, Pagovich OE, Rosenberg JB, De BP, et al. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Science Translational Medicine. 2020;12(572):eabb5413.

El-Hage N, Haney MJ, Zhao Y, Rodriguez M, Wu Z, Liu M, et al. Extracellular Vesicles Released by Genetically Modified Macrophages Activate Autophagy and Produce Potent Neuroprotection in Mouse Model of Lysosomal Storage Disorder, Batten Disease. Cells [Internet]. 2023; 12(11).

Bartsch U. Strategies to treat neurodegeneration in neuronal ceroid lipofuscinosis: a view onto the retina. Neural Regen Res. 2023;18(3):558-559.

Liu J, Bassal M, Schlichting S, Braren I, Di Spiezio A, Saftig P, et al. Intravitreal gene therapy restores the autophagy-lysosomal pathway and attenuates retinal degeneration in cathepsin D-deficient mice. Neurobiol Dis. 2022;164:105628.

Mitchell NL, Murray SJ, Wellby MP, Barrell GK, Russell KN, Deane AR, et al. Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease. Frontiers in Genetics. 2023;14.

Jana M, Dutta D, Poddar J, Pahan K. Activation of PPARα Exhibits Therapeutic Efficacy in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis. J Neurosci. 2023;43(10):1814-1829.

Larsen EP, Østergaard JR. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease). Seizure. 2014;23(6):429-434.